This double-blind, placebo-controlled trial (n=45) will study the safety and efficacy of two dosage levels of intravenous (2R,6R)-Hydroxynorketamine (RR-HNK) in adults with obsessive-compulsive disorder (OCD).
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Randomized, parallel-group, triple-masked Phase I/II trial comparing single IV infusions of 0.25 mg/kg and 0.5 mg/kg RR-HNK versus sterile saline placebo in adults with OCD; EEG and computerized behavioural tests acquired before and after infusion.
Single IV infusion of 0.25 mg/kg RR-HNK with EEG and computerized behavioural tests pre/post.
Single IV infusion; EEG and computerized behavioural tests before and after infusion.
Single IV infusion of 0.5 mg/kg RR-HNK with EEG and computerized behavioural tests pre/post.
Single IV infusion; EEG and computerized behavioural tests before and after infusion.
Single IV infusion of sterile saline (placebo) with EEG and computerized behavioural tests pre/post.
Sterile saline single IV infusion (placebo).